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Vanishing bone diseaseGorham–Stout disease (GSD) is a rare disorder characterized by the proliferation of endothelial-lined vessels in
bone and the progressive destruction of bone. Although Jackson described the ﬁrst case of GSD in 1838, the clin-
ical and histological features of GSDwere not deﬁned until Gorham and Stout published their report on massive
osteolysis in 1955. In the years since Gorham and Stout's groundbreaking publication, more than 300 cases of
GSD have been described in the literature. These reports have revealed that the progressive resorption of bone
in GSD causes severe physical deformities, disabilities, and life-threatening complications. Unfortunately, the
underlying cause of GSD remains unknown and, as a result, the therapeutic options for individuals with GSD
are limited. Here we review the latest advances in GSD research and present strategies to address basic and clin-
ical research questions related to GSD.
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Gorham–Stout disease (GSD, also known as massive osteolysis,
vanishing bone disease, phantom bone disease, Gorham's disease and
Gorham–Stout syndrome) is a rare disease of unknown etiology charac-
terized histologically by the proliferation of endothelial-lined vessels in
bone and by the replacement of bone with ﬁbrous tissue [1]. In 1838,
J.B.S. Jackson published the ﬁrst case of GSD [2]. In his paper titled “Aense.
48 M.T. Dellinger et al. / Bone 63 (2014) 47–52Boneless Arm”, Jackson describesMr. Brown, a patientwhose entire hu-
merus gradually disappeared over a period of several years [2]. Over
100 years would pass before another substantial report on massive
osteolysis would be published [3]. In 1954, Gorham and colleagues pub-
lished a report on the histological changes they observed in a patient
with massive osteolysis [3]. They found that several of the affected
bones from their patient displayed a dramatic increase in vascularity
[3]. This crucial ﬁnding, as well as previous reports describing vascular
changes accompanying massive osteolysis [4–8], prompted Gorham
and Stout to further deﬁne the histological and clinical features of mas-
sive osteolysis. By evaluating histological samples from 8 previously
studied cases, Gorham and Stout were able to ﬁrmly establish that mas-
sive osteolysis is accompanied by the extensive proliferation of
endothelial-lined channels in bone [1]. Furthermore, by reviewing an
additional 16 cases from the literature, they were able to provide the
ﬁrst detailed report on the clinical features of this rare disease [1]. De-
spite advances in clinical and basic science research since Gorham and
Stout's publication in 1955, much still remains unknown about the
pathology of GSD. This lack of knowledge has hindered the identiﬁca-
tion of effective therapies for treating this devastating disease. To
address this need, the Lymphatic Malformation Institute (LMI) and
Lymphangiomatosis & Gorham's Disease Alliance (LGDA) recently
sponsored an international scientiﬁc conference focused on developing
strategies to address many of the basic and clinical research questions
related to GSD. In this review we summarize clinical information for
185 previously published cases of GSD, highlight the latest advances in
GSD research and address unanswered questions related to GSD.
Clinical features of GSD
GSD can present at any age (age range is from 7 months to
83 years), but is most commonly diagnosed in children and young
adults (average age of diagnosis is 25 years; Supplemental Table 1).
The disease does not display a clear sex predilection (1.6:1 male-to-
female ratio; Supplemental Table 1) or inheritance pattern [9]. Although
GSD can affect any bone in the body, it frequently affects the maxilla,
mandible, clavicle, ribs, cervical vertebrae, pelvis and femur (Supple-
mental Table 1). Areas of bone resorption can arise in a single bone or
inmultiple contiguous bones (Supplemental Table 1). Osteolytic lesions
in patients with GSD initially appear as small radiolucent foci in radio-
graphic images [10]. These foci enlarge and coalesce as the disease pro-
gresses [10]. Additionally, tubular bones undergo concentric shrinkage
causing them to have a “sucked candy” appearance. In severe cases,
this process continues until the entire bone is resorbed and replaced
by ﬁbrous tissue. Eventually, for reasons that are not entirely clear, the
disease can spontaneously arrest and stabilize. Importantly, new bone
does not form to a notable extent after the disease has stabilized [1].
The symptoms of GSD vary and depend on which sites in the body
are affected. Themost common symptom is localized pain (Supplemen-
tal Table 1). Other symptoms include swelling, weakness and functional
impairment of affected limbs. GSD patients may be asymptomatic until
they suffer a bone fracture either spontaneously or following minor
trauma. Patients with thoracic involvementmay seekmedical attention
because they have difﬁculty breathing. This is typically caused by
chylothorax, an accumulation of chyle (lymph rich in fat) in the pleural
cavity [11]. Approximately 25% of GSD patients develop chylothorax,
which can result in respiratory distress and failure (Supplemental
Table 1). Additionally, involvement of the vertebrae can cause severe
neurological defects, deformity, paralysis, and death.
Histological features of GSD
Gorham and Stout evaluated biopsy specimens from 8 previously re-
ported cases of massive osteolysis to determine whether these patients
displayed similar histopathological alterations in their affected tissues.
They observed that the affected bone, and the ﬁbrous tissue that hadreplaced bone, contained numerous dilated endothelial-lined vessels
[1]. Numerous other investigators have observed the same changes
in sections of affected bones stained with hematoxylin and eosin. How-
ever, the identity of the deranged vessels differs from case to case. In
some cases, the abnormal channels are reported to be blood vessels
[1,3,12–14] whereas in other cases they are reported to be lymphatic
vessels [4,15–17]. The emergence of immunohistochemical markers of
lymphatic endothelial cells has greatly facilitated the characterization
of the abnormal vessels in GSD. Two commonly usedmolecularmarkers
of lymphatic endothelial cells are LYVE-1, a receptor for the glycosami-
noglycan hyaluronan, and podoplanin, a transmembrane glycoprotein
recognized by the antibody D2-40 [18,19]. Thesemarkers have revealed
that lymphatic vessels are not present in normal bones [20], but are
present in medullary and cortical regions of bones in patients with
GSD [20–25]. Affected soft tissues in GSD patients also display abnormal
lymphatic vessels [26,27]. Although numerous lymphatic vessels
are present in affected tissues in GSD, they are not widely labeled by
MIB-1, a monoclonal antibody against the proliferation marker Ki-67
[21,28]. Therefore, according to the International Society for the Study
of Vascular Anomalies (ISSVA) classiﬁcation system, the lymphatic
anomaly in GSD is a malformation rather than a tumor [21]. Together,
these observations suggest that lymphatic vessels rather than blood
vessels are primarily affected in GSD.
Etiology of GSD
The cause of excessive bone resorption in GSD is unclear. In the
following sections we discuss the potential role of endothelial cells,
osteoclasts and osteoblasts in the pathogenesis of GSD (Fig. 1).
Endothelial cells
Several investigators have proposed that the abnormal endothelial-
lined channels in osteolytic zones promote bone resorption. Gorham
and Stout believed that the local proliferation of endothelial-lined
vessels could promote bone loss by increasing blood ﬂow, changing
local pH, or by exerting mechanical force [1]. Heyden et al. proposed
that sluggish blood ﬂow in osteolytic areas might cause local hypoxia,
which could lower tissue pH and favor the activity of hydrolytic en-
zymes [29]. Importantly, these ideas attempt to explain how blood ves-
sels could promote bone loss in GSD. However, there is mounting
evidence that lymphatic vessels are primarily affected in GSD. The
uncontrolled growth of ﬂuid-ﬁlled lymphatic vessels could cause
osteolysis by compressing bone. Alternatively, lymphatic endothelial
cells may secrete factors that inﬂuence the activity of osteoclasts and/or
osteoblasts.
Lymphangiogenesis, which is the sprouting of new lymphatic vessels
from pre-existing vessels, occurs in an uncontrolled fashion in GSD. This
process is driven, in part, by growth factors in the microenvironment
that activate receptors on the surface of lymphatic endothelial cells.Mem-
bers of the vascular endothelial growth factor (VEGF) family are thought
to be the most important factors that drive lymphangiogenesis [30–32].
One prominent lymphangiogenic member of this family is VEGF-C, a
ligand of the receptor tyrosine kinases VEGFR2 and VEGFR3 [33,34]. Al-
though the signaling pathways stimulating lymphangiogenesis in many
pathological settings have been characterized, the pathways driving
lymphangiogenesis in GSD have not been deﬁned. It is possible that a
local increase in the level of VEGF-C or of another pro-lymphangiogenic
factor (VEGF-A, -D, Ang-1, -2, etc.) could stimulate lymphangiogenesis
in GSD [35–38]. Indeed, VEGF-C has been found to be elevated in the
serum of one GSD patient [27] and VEGF-A has been found to be elevated
in the serum of three GSD patients [27,39] and in the plasma of another
patient [40] (Table 1). Alternatively, a decrease in the level of an anti-
lymphangiogenic factor (sVEGFR2 [41], TGF-β [42], IFN-γ [43], etc.)
could promote the uncontrolled growth of lymphatic vessels in the
bones of patients with GSD.
Fig. 1.Diagram illustrating cells and interactions that likely contribute to the diseasemechanism in GSD. The proliferation of lymphatic endothelial cells (LECs) and blood endothelial cells
(BECs) could be stimulated by increased levels of VEGF-C, and -D andmacrophage-derived VEGF-A. Macrophages may also contribute to the formation of LECs and are the progenitors of
osteoclasts (block arrows). In addition, they produce VEGF-A, -C, and -D and interleukin 6 (IL-6); all stimulate osteoclast differentiation. Osteoblast progenitor cells may be inhibited in
their differentiation and function by factors secreted by LECs and by factors produced by osteocytes, including sclerostin, and Dickkopf- and soluble frizzled-related proteins. Although
low levels of TNF-α can stimulate stromal cell recruitment and osteogenic differentiation [91], high levels of TNF-α produced by macrophages inhibit osteoblast differentiation and
enhance osteoclastogenesis by stimulating RANKL production by stromal cells.
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Osteoclasts are multi-nucleated cells, differentiated from myeloid
progenitors, that resorb bone by locally secreting proteolytic enzymes
and hydrogen ions [44]. Several growth factors and cytokines regulate
their differentiation and activity, including the stimulatory factors
CSF-1 (M-CSF), RANKL, IL-6, TNF-α, VEGF-A and VEGF-C and the inhib-
itory factor osteoprotegerin (OPG). Hyperactive osteoclasts participate
in the pathogenesis of several human skeletal disorders in which bone
is lost, including cherubism [45], familial expansile osteolysis [46], and
juvenile Paget disease (also known as familial hyperphosphatasia)
[47]. However, there are conﬂicting reports on whether osteoclasts
are present in osteolytic zones in GSD. In fact, while some investigators
have observed osteoclasts in osteolytic zones [12,13,21,48–56], Gorham
and Stout, as well as other investigators, have reported that osteoclasts
are not present in areas of bone resorption [1,15,29,57,58]. The reason
for this discrepancy is unclear, but it has been proposed that it may beTable 1
Circulating levels of biomarkers in patients with Gorham–Stout disease.
Protein Level during active phase of disease Level during inactive ph
VEGF-A 163 pg/ml (Plasma) 25 pg/ml (Plasma)
VEGF-A 277 pg/ml (Serum) 161 pg/ml (Serum)
VEGF-A 730 pg/ml (Serum) 570 pg/ml (Serum)
VEGF-A 1200 pg/ml (Serum) 370 pg/ml (Serum)
VEGF-A 100 pg/ml (Serum) N/A
VEGF-C 4050 pg/ml (Serum) 3910 pg/ml (Serum)
VEGF-C 6930 pg/ml (Serum) 2260 pg/ml (Serum)
PDGF-BB 108 pg/ml (Serum) N/A
IL-6 7 pg/ml (Serum) 15 pg/ml (Serum)
IL-6 6.7 times higher than the upper
limit of the normal range
1.9 times higher than th
limit of the normal rang
IL-6 8.4 pg/ml (Serum) b5.4 pg/ml (Serum)
IL-6 7 times higher than the upper
limit of the normal range
1.75 times higher than t
limit of the normal rang
IL-6 71.1 pg/ml (Serum) N/Adue to evaluations being conducted at different phases (active versus
stable) of the disease [59].
Whether this explanation is correct is not clear, but studies of some
cases of GSD suggest that patient osteoclast progenitor cells may be
more sensitive to the osteoclast-inducing factors CSF-1 and RANKL
than control cells [51] and that patient serum can induce osteoclast for-
mation in an IL-6-dependent manner [60]. In addition, histochemistry
and electron microscopy of tissue isolated from GSD bone lesions indi-
cate the presence of an increased number of pericyte/macrophage-like
mononuclear cells with abundant acid phosphatase positive lysosomal
bodies [29,61]. These macrophage-like cells may serve as progenitors
of osteoclasts in GSD lesions. In addition, macrophages are known to
produce VEGF-A, VEGF-C and VEGF-D [62] and all three factors are
able to stimulate osteoclast differentiation and lymphangiogenesis
[63–65]. Finally, in an inﬂammatory environment macrophages may
even directly contribute to lymphangiogenesis by expressing markers
of lymphatic endothelium and forming tube-like structures [66,67].ase of disease Reported normal value(s) Reference
1–63 pg/ml (Plasma) Dupond et al. [40]
50 pg/ml (Serum) Morimoto et al. [39]
62–707 pg/ml (Serum) Brodszki et al. [27]
62–707 pg/ml (Serum) Brodszki et al. [27]
N/A Hagendoorn et al. [26]
2459–6651 pg/ml (Serum) Brodszki et al. [27]
2459–6651 pg/ml (Serum) Brodszki et al. [27]
15 pg/ml (Serum) Hagendoorn et al. [26]
b8 pg/ml (Serum) Brodszki et al. [27]
e upper
e
N/A Plasswilm et al. [76]
b5.0 pg/ml (Serum) Hammer et al. [50]
he upper
e
N/A Devlin et al. [60]
b4.0 pg/ml (Serum) Fujiu et al. [15]
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A remarkable aspect of the osteolytic process in GSD is the absence
of evidence for increased osteoblast activity along surfaces of remaining
bone fragments in sections of affected tissues [61]. This is quite different
from other skeletal disorders with bone loss due to increased differenti-
ation and activity of osteoclasts. For example, the massive loss of maxil-
lary and mandibular bones in cherubism, caused by mutations that
result in increased sensitivity of myeloid cells to macrophage- and
osteoclast-inducing signals [45], is associated with a robust increase in
osteoblast activity. In active GSD lesions the disappearing bone is re-
placed by ﬁbrovascular tissue rather than newly formed woven repair
bone. Particularly striking are observations that osteoblastic cells within
active lesions exhibit ultrastructural features suggesting that they have
either decreased synthetic activity or are degenerating [61]. Finally,
osteocytes within bone tissue close to the lesions have been reported
to having pyknotic nuclei and occupying enlarged lacunae [29,61].
This lack of an osteoblastic repair response in GSD lesions is particu-
larly puzzling in view of the high circulating levels of VEGF-A reported
for many GSD patients [27,40,68] and the strong evidence that VEGF-A
stimulates bone repair by promoting angiogenesis and bone turnover
[69]. Also puzzling is that this loss of an osteoblastic response is restrict-
ed to the vanishing bone(s), while bone homeostasis appears to be rel-
atively unaffected in other parts of the skeleton. This suggests that the
pathophysiological events causing osteolysis in GSD are localized and
that factors produced in the processmight stimulatemesenchymal pro-
genitors to differentiate along the ﬁbroblastic, rather than osteoblastic
lineage. The role of osteocytes in regulating osteoblast differentiation
and activitymay be important in this context. Osteocytes release factors
that stimulate osteoblast differentiation [70,71] and recruitment ofmes-
enchymal stem cells to bone fracture sites [72] and they inhibit osteo-
blast differentiation by producing Wnt signaling inhibitors such as
sclerostin, Dickkopf-related proteins and soluble frizzled-related pro-
teins [73]. Thus, it is possible that changes in such osteocyte-produced
factorsmay contribute to the lack of osteoblastic repair responses inGSD.
Genetics and GSD
GSD is a sporadic disease potentially caused by speciﬁc genetic risk
factors or by mosaicism for a somatic mutation. Approaches that have
been used to identify the genetic basis of other sporadic diseases could
be used to search for mutations that may be contributing to GSD. For ex-
ample, Proteus and CLOVES are two sporadic overgrowth syndromes
caused by somatic activatingmutations in AKT1 and PIK3CA, respectively
[74,75]. These mutations were found by sequencing DNA puriﬁed from
affected tissues. Importantly, the disease causing mutations were not
present in DNA isolated from the blood or saliva of patients. Therefore,
it has been suggested that DNA puriﬁed from affected tissues, rather
than blood or saliva, be analyzed to search for the potential genetic un-
derpinnings of GSD. Unfortunately, affected bones from GSD patients
are frequently ﬁxed, decalciﬁed with acid, and embedded in parafﬁn,
which makes exome sequencing technically challenging. To overcome
this obstacle, it has been recommended that DNA from fresh tissues or
from cell lines derived from affected tissues be used in exome sequenc-
ing experiments. Identiﬁcation of mutations associated with GSD
would help direct the development of animal models and the search
for therapeutic strategies.
Biomarkers for monitoring the activity of GSD
The clinical course of GSD is unpredictable. In some patients the
disease progresses slowly whereas in others it progresses rapidly and
causes severe disability. A current challenge in the clinic is identifying
which patients fall into the latter category and require close monitoring
and aggressive treatment. To address this problem, several studies have
examinedwhether lymphangiogenic and osteoclastogenic factors couldserve as biomarkers of disease activity in GSD. Most of these reports
have centered on the growth factor VEGF-A [27,39,40] and the cytokine
IL-6 [15,50,60,76]. These studies have shown that VEGF-A and IL-6 can
be elevated in the circulation of patients with GSD and that the level
of these factors can decrease following treatmentwith various therapies
(Table 1). However, VEGF-A [26] and IL-6 [27] are not elevated in all
GSD patients. Therefore, additional factors are being analyzed with the
hope of ﬁnding additional biomarkers. Other factors evaluated in the
circulation of GSD patients include VEGF-C [27], PDGF-BB [26], sRANKL
[50], and osteoprotegerin [50] (Table 1). While the clinical diversity of
GSD makes it unlikely that a single biomarker for all GSD patients can
be found, a universal set of biomarkers to monitor disease activity
could provide diagnostic, prognostic or predictive information.
Therapies for treating GSD
Depending on the severity of the disease, the extent of organ-
involvement and other signs, different strategies are used to treat GSD.
These strategies include surgery, radiotherapy and pharmaceuticals
(Supplemental Table 1). Surgery for GSDmainly consists of interventions
to reduce or halt ﬂuid build-up in the pleural cavity and these interven-
tions include pleurectomy, pleurodesis, thoracentesis, and thoracic duct
embolization or ligation [9]. Surgery is also performed to stabilize affect-
ed regions of the skeleton once the disease appears to have stabilized
[77]. Radiotherapy has been used in cases where surgery is not possible
or in combination with surgery [78–80]. Several case reports have de-
scribed the successful use of radiotherapy, with an overall success rate
in the case of local lesions being about 75% [78]. A total of 36–45 Gy,
given in 2 Gy portions, appears to provide the most therapeutic beneﬁt
[78,79,81,82]. Several pharmaceuticals have also been used to treat pa-
tients with GSD [9]. However, since pharmaceuticals are most often
used in combination with other therapeutic approaches, it is difﬁcult to
assess the beneﬁt of the administered pharmaceutical(s). Moreover, a
consensus regarding the effectiveness of speciﬁc pharmaceuticals cannot
be derived from a review of the available literature. Themost commonly
prescribed pharmaceuticals to treat GSD are bisphosphonates and
interferon alpha 2b [23,26,48,50,83–86]. These have been used as
single agents or in combination with one another. Other pharmaceuti-
cals that have been used to treat GSD include the anti-VEGF-A antibody,
Bevacizumab [87], propranolol [88], lowmolecularweight heparin [27],
steroids, vitamin D, and calcitonin [9].
Clinical trials are needed to test the efﬁcacy of existing and emerging
therapies against GSD. An ongoing clinical trial is testing the efﬁcacy of
themTOR inhibitor rapamycin (Sirolimus) in children and young adults
with several different vascular anomalies involving bone, including GSD
(www.clinicaltrials.gov; NCT00975819) [89,90]. Preliminary, but prom-
ising, ﬁndings from this trial were presented at the 1st International
Conference on Generalized Lymphatic Anomaly and Gorham–Stout
Syndrome held in Bethesda, MD in June 2013 and the ﬁnal results
from the study are expected in mid-2014. In the future, the recently
launched Lymphangiomatosis & Gorham's Disease Alliance global pa-
tient registry (www.LGDARegistry.org) and Boston Children's Hospital
lymphatic anomalies registry (contact the Vascular Anomalies Center
at BCH for more information) could help gather patients for new trials.
GSD and generalized lymphatic anomaly
Generalized lymphatic anomaly (GLA, also known as lymph-
angiomatosis) is a rare disease highly related to GSD. GLA is
characterized by the extensive proliferation of lymphatic vessels and
frequently affects bone. A retrospective review of 32 GLA and 19 GSD
patients in the Vascular Anomalies Center database at Boston Children's
Hospital revealed that GLA and GSD patients display differences in bone
disease [25]. GLA patients display lytic areas conﬁned to the medullary
cavity whereas GSD patients display progressive osteolysis resulting in
the loss of cortical bone [25]. GLA patients typically have more bones
51M.T. Dellinger et al. / Bone 63 (2014) 47–52involved than GSD patients and the appendicular skeleton is more fre-
quently involved in GLA than GSD patients [25]. Macrocystic lymphatic
malformations are also more frequently observed in GLA than GSD pa-
tients [25]. Affected bones fromGLA and GSD patients display abnormal
lymphatic channels and appear similar to one another histologically
[25]. Continued study of GLA and GSD will help delineate the clinical,
histological, and genetic similarities and differences between these
two rare diseases.
Concluding remarks
Our understanding of the features of GSD has increased dramatically
since Gorham and Stout's publication in 1955. Case reports and case
series have shed light on the disease process, identiﬁed potential bio-
markers for monitoring disease activity, and pointed towards speciﬁc
therapies for treating GSD. Despite these advances, much still remains
unknown about GSD. The molecular mechanisms driving osteolysis
and lymphangiogenesis in GSD remain unclear, a genetic basis of GSD
has not been deﬁned, and there are no FDA approved therapies for
treating GSD. Importantly, numerous research projects are currently
underway to address these and other basic science and clinical research
questions. Together, these efforts will lead to a deeper understanding of
the etiology of GSD and help identify therapies to treat patients suffer-
ing from this insidious disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2014.02.011.
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